In its third-quarter SEC filing, Banyan Capital Management disclosed the acquisition of 3,853 shares of Johnson & Johnson, representing an investment of approximately 714,000 dollars. This new position constitutes roughly 0.3 percent of Banyan’s overall portfolio and ranks as its twenty-second largest holding. The move underscores the hedge fund’s selective interest in stable, dividend-paying blue-chip healthcare names during the recent quarter.

Several major institutions reshuffled their Johnson & Johnson holdings in the second quarter. Norges Bank initiated a 4.88-billion-dollar stake, while Laurel Wealth Advisors increased its position by a staggering 15,040.6 percent to 7.42 million shares, valued at 1.13 billion dollars after adding 7.37 million shares. Vanguard Group added 3.09 million shares to reach a 237.05 million-share holding worth 36.21 billion dollars, and Geode Capital Management bought 1.23 million shares, raising its stake to 60.61 million shares valued at 9.23 billion dollars. Legal & General boosted its position by 6.2 percent to 18.92 million shares, a 2.89-billion-dollar holding. Collectively, institutional investors now own nearly 70 percent of the company’s stock.

In Europe, the Committee for Medicinal Products for Human Use issued a favorable opinion on the company’s combination therapy for BRCA-mutant metastatic prostate cancer, opening the door for a new oncology revenue stream. Domestically, a federal judge dismissed a fraud lawsuit challenging the company’s talc-related bankruptcy strategy, removing a near-term overhang on litigation risk. While commentators caution that broader legal challenges remain unresolved, these developments have reduced uncertainty around the company’s pharmaceutical and liability outlook.

In recent weeks, Daiwa Capital Markets reiterated an outperform rating and raised its price target to 237 dollars, Morgan Stanley upgraded its recommendation citing an improved growth trajectory, and Scotiabank lifted its target to 265 dollars following strong fourth-quarter results. On January 21, the company reported quarterly revenue of 24.56 billion dollars—a 9.1 percent year-over-year increase—and earnings per share of 2.46, matching consensus forecasts. Management issued guidance of 11.43 to 11.63 dollars in full-year earnings per share, while the board declared a 1.30-dollar quarterly dividend, representing a 5.20-dollar annualized payout and a yield of approximately 2.3 percent.